Christina Burke, PA
Medical · Saint Petersburg, FLNPI 1356390785
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Viiv Healthcare Company at 43.9% of the total. 2025 is the largest year on record at $2,125, 3.3 times the $643 reported in 2021. Among medical clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$2K
- Theratechnologies Inc.$720
- AbbVie$308
- Johnson & Johnson$219
- Merck$188
- plus $469 from 8 others
Across 3 payments — averaging $2606.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$8K
What the payments were for
- Food & beverage$7,11197%
- Education$310%
- Gifts$1762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 151 | $3,216 |
| Gilead | 93 | $2,198 |
| Theratechnologies Inc. | 34 | $720 |
| AbbVie | 14 | $308 |
| Johnson & Johnson | 13 | $219 |
| Merck | 6 | $188 |
| Napo Pharmaceuticals Inc | 6 | $134 |
| Harmony Biosciences LLC | 1 | $123 |
| Exact Sciences | 3 | $63 |
| Coastal Medical Technologies LLC | 1 | $44 |
| Janssen Products, LP | 1 | $31 |
| Janssen Scientific Affairs, LLC | 2 | $28 |
| Alfasigma USA, Inc. | 1 | $24 |
| GSK | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,319 in reported general payments places this provider in the 90th percentile of 2,031 medical providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 677 | $2,589,466 |
| DovatoDolutegravir Sodium/Lamivudine | 135 | $384,639 |
| PrezcobixDarunavir/Cobicistat | 157 | $375,733 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 109 | $372,062 |
| CabenuvaCabotegravir/Rilpivirine | 48 | $286,413 |
| TivicayDolutegravir Sodium | 110 | $247,898 |
| JulucaDolutegravir/Rilpivirine | 66 | $223,170 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 43 | $190,399 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 37 | $129,412 |
| RukobiaFostemsavir Tromethamine | 14 | $126,266 |
| DescovyEmtricitabine/Tenofov Alafenam | 46 | $104,032 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 26 | $95,606 |
| PifeltroDoravirine | 32 | $56,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,905 |
| Atazanavir Sulfate | 13 | $7,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $2,198 | $2,822,911760 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay, Juluca, Rukobia | $3,216 | $1,363,991399 claims |
| Johnson & JohnsonPrezcobix | $219 | $375,733157 claims |
| Janssen Products, LPSymtuza | $31 | $190,39943 claims |
| MerckPifeltro | $188 | $56,42032 claims |
| GSKTrelegy Ellipta | $22 | $7,90513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,031 medical providers in Florida.
Other medical in Saint Petersburg
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.